ABOS Acumen Pharmaceuticals Inc.

14.33
-0.23  -2%
Previous Close 14.56
Open 14.65
52 Week Low 12.7
52 Week High 26.98
Market Cap $579,907,687
Shares 40,468,087
Float 28,849,266
Enterprise Value $504,216,111
Volume 32,106
Av. Daily Volume 188,088
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
ACU193
Alzheimer’s disease
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Latest News

  1. ACU193 is the first monoclonal antibody to enter a clinical trial that was discovered and is being developed to selectively target toxic amyloid-beta oligomers (AβOs)

    Enrollment of early Alzheimer's patients is ongoing in INTERCEPT-AD, the Phase 1 placebo-controlled, single- and multiple-dose clinical trial of ACU193

    CHARLOTTESVILLE, Va. and CARMEL, Ind., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today announced dosing of the first patient in INTERCEPT-AD, the Phase 1 placebo-controlled, single- and multiple-dose clinical trial of ACU193, a monoclonal antibody that selectively targets toxic…

    ACU193 is the first monoclonal antibody to enter a clinical trial that was discovered and is being developed to selectively target toxic amyloid-beta oligomers (AβOs)

    Enrollment of early Alzheimer's patients is ongoing in INTERCEPT-AD, the Phase 1 placebo-controlled, single- and multiple-dose clinical trial of ACU193

    CHARLOTTESVILLE, Va. and CARMEL, Ind., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today announced dosing of the first patient in INTERCEPT-AD, the Phase 1 placebo-controlled, single- and multiple-dose clinical trial of ACU193, a monoclonal antibody that selectively targets toxic amyloid-beta oligomers (AβOs) for the treatment of early AD.

    "We are very pleased to report this first clinical development milestone for ACU193," said Daniel O'Connell, President and CEO of Acumen. "We are encouraged by recent momentum and the breadth of scientific innovation that is being applied to Alzheimer's research. We believe ACU193 has distinct potential to address the continued unmet medical needs of people living with Alzheimer's disease."

    ACU193 is a monoclonal antibody (mAb) discovered and developed based on its selectivity for AβOs, which Acumen believes are the most toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques. AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic AβOs, ACU193 aims to directly address what a growing body of evidence indicates is a primary underlying cause of the neurodegenerative process in AD.

    "We are all very excited about evaluating ACU193 in the INTERCEPT-AD trial," said Eric Siemers MD, Chief Medical Officer for Acumen. "Our goal for this Phase 1 clinical trial is to establish proof of mechanism for ACU193, including overall safety and tolerability, pharmacokinetics and target engagement. We have also incorporated standard clinical outcomes for AD as well as exploratory assessments. Based on ACU193's unique mechanism of action, we believe it has the potential for improved efficacy and for improved safety compared to other monoclonal antibodies in development."

    About INTERCEPT-AD

    Approximately 62 individuals with early AD (mild cognitive impairment or mild dementia due to AD) are expected to be randomized into this double-blind, placebo-controlled, first-in-human study of ACU193. INTERCEPT-AD is designed to establish safety and proof of mechanism. It consists of single-ascending-dose (SAD) and multiple-ascending-dose (MAD) cohorts and is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and target engagement of intravenous doses of ACU193. The study is enrolling at multiple investigative sites located in the United States. More information can be found on www.clinicaltrials.gov, NCT identifier NCT04931459.

    About Acumen Pharmaceuticals, Inc.

    Acumen, headquartered in Charlottesville, VA, with clinical operations based in Carmel, IN, is a clinical stage biopharmaceutical company developing a novel disease-modifying approach to treat Alzheimer's disease. Acumen's scientific founders pioneered research on AβOs, which a growing body of evidence indicates are primary triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its investigational immunotherapy drug, ACU193, a humanized monoclonal antibody that selectively targets toxic AβOs in a Phase I clinical trial involving early Alzheimer's disease patients.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.  Any statement describing Acumen's goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as "believes," "expects," "anticipates," "could," "would," "seeks," "aims," "plans," "potential," "will" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning Acumen's business and the therapeutic potential of Acumen's product candidate, ACU193, including its potential for improved safety and efficacy as compared to other monoclonal antibodies in development, as well as the expectations concerning the INTERCEPT-AD trial. These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of the COVID-19 pandemic. These and other risks concerning Acumen's programs are described in additional detail in Acumen's filings with the Securities and Exchange Commission ("SEC"), including in Acumen's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed with the SEC on August 16, 2021, which is available on the SEC's website at www.sec.gov. Copies of these and other documents are available from Acumen.  Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise.

    Contact: investors@acumenpharm.com 

    For more information, visit www.acumenpharm.com.



    Primary Logo

    View Full Article Hide Full Article
    • Acumen's investigational drug, ACU193, is the first humanized monoclonal antibody discovered and developed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical trials
    • Initiated ACU-001, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193 in patients with early Alzheimer's Disease
    • Closed initial public offering in July 2021, with aggregate net proceeds of $169 million

    CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) (Acumen), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today reported financial…

    • Acumen's investigational drug, ACU193, is the first humanized monoclonal antibody discovered and developed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical trials
    • Initiated ACU-001, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193 in patients with early Alzheimer's Disease
    • Closed initial public offering in July 2021, with aggregate net proceeds of $169 million

    CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) (Acumen), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today reported financial results for the quarter ended June 30, 2021 and provided recent business highlights.

    "We continue to execute on our corporate and clinical development goals during this exciting time in the Alzheimer's field," said Daniel O'Connell, President and Chief Executive Officer at Acumen. "Our clinical trial, ACU-001, is investigating the safety, tolerability, pharmacokinetics, and target engagement of our product candidate ACU193 in a Phase 1 clinical trial involving early Alzheimer's patients. ACU193 is the first humanized monoclonal antibody discovered and developed to selectively target toxic amyloid-beta oligomers (AβOs) to enter a clinical trial. We anticipate ACU-001 recruitment and cohort progression will allow us to provide topline results with the goal of demonstrating ‘proof of mechanism' for ACU193 in early AD by year end 2022. With the recent closing of our IPO, we believe we are well-funded to achieve multiple corporate and clinical development milestones, as we execute against our comprehensive strategic plan."

    Recent Business Highlights and Anticipated Milestones

    ACU193 Clinical Development

    • ACU-001 trial is actively recruiting and we expect to report top-line data by year end 2022.  Patient screening and enrollment is proceeding for the randomized, placebo-controlled Phase 1 clinical trial evaluating ACU193.  

    Corporate

    • Prefunding of Series B Milestone Tranche - $30M. On June 17, 2021, the Milestone Closing for the Series B convertible preferred stock occurred, resulting in the sale of 7,908,027 shares of Series B convertible preferred stock for gross proceeds of $30.0 million. The Series B investors included RA Capital, PBM Capital, BlackRock, and Sands Capital.
    • Closing of Initial Public Offering. In July 2021, Acumen issued an aggregate of 11,499,998 shares of common stock, including shares pursuant to the underwriters' exercise of their full over-allotment option, in an initial public offering (IPO), resulting in aggregate net proceeds of $168.6 million.

    Second Quarter 2021 Financial Results

    • Cash Balance. Cash, cash equivalents and marketable securities were $68.8 million as of June 30, 2021, compared to $43.8 million as of December 31, 2020. The net proceeds of the IPO resulted in total cash, cash equivalents and marketable securities increasing to more than $235 million in early July 2021.
    • Research and Development (R&D) Expenses. R&D expenses were $2.3 million and $4.8 million for the three- and six-month periods ending June 30, 2021, respectively, compared to $1.9 million and $4.0 million for the three- and six-month periods ending June 30, 2020, respectively.
    • General and Administrative (G&A) Expenses.  G&A expenses were $1.2 million and $2.4 million for the three- and six-month periods ending June 30, 2021, respectively, compared to $0.3 million and $0.5 million for the three- and six-month periods ending June 30, 2020, respectively.
    • Net Operating Loss.  Net Operating Losses were $3.4 million and $7.2 million for the three- and six-month periods ending June 30, 2021, respectively, compared to $2.0 million and $4.1 million for the three- and six-month periods ending June 30, 2020, respectively.
      • Net Loss. Net Losses were $61.4 million and $88.4 million for the three-and six-month periods ending June 30, 2021, respectively, compared to $2.0 million and $4.1 million for the three- and six-month periods ending June 30, 2020, respectively. Net losses in 2021 include a non-cash expense that represents the changes in fair value of Acumen's Series A-1 warrant liability and the Series B tranche rights. The warrant liability and tranche rights were initially recorded at fair value as a liability on the company's balance sheet and were subsequently re-measured at fair value at the end of each reporting period. The increases in the fair value of these instruments were recognized as a component of other expense.

    About Acumen Pharmaceuticals, Inc.

    Acumen, headquartered in Charlottesville, VA with clinical operations based in Carmel, IN, is a clinical stage biopharmaceutical company developing a novel disease-modifying approach to treat Alzheimer's disease.  Acumen's scientific founders pioneered research on AβOs, which a growing body of evidence indicates are primary triggers of Alzheimer's disease pathology.  Acumen is currently focused on advancing its investigational drug, ACU193, a humanized monoclonal antibody that selectively targets toxic AbOs, in a Phase I clinical trial involving early Alzheimer's disease patients.   We believe that ACU193 represents a differentiated approach from current and prior AD immunotherapies because it is highly selective for toxic AβOs and because it is engineered to reduce immune signaling. As such, ACU193 is expected to carry a reduced rate of amyloid-related imaging abnormalities, or ARIA, a common, dose-limiting adverse event observed with amyloid plaque-targeting immunotherapies.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen's goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as "believes," "expects," "anticipates," "could," "would," "seeks," "aims," "plans," "potential" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning Acumen's business, our ability to achieve our strategic and financial goals, the therapeutic potential of Acumen's product candidate, ACU193, and the expected timing of reporting top line data from the Phase 1 clinical trial of ACU193. These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of the COVID-19 pandemic. These and other risks concerning Acumen's programs are described in additional detail in Acumen's filings with the Securities and Exchange Commission (SEC), including in our prospectus dated June 30, 2021, as filed with the SEC on July 2, 2021, pursuant to Rule 424(b) under the Securities Act of 1933, which is available on the SEC's website at www.sec.gov. Copies of these and other documents are available from the Company. Additional information will be made available in other filings that we make from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether as a result of new information, future events or otherwise.

    Investor & Media Contact:

    investors@acumenpharm.com



    Acumen Pharmaceuticals, Inc.
    Condensed Balance Sheets
    (in thousands, except share and per share data)
        
     June 30, 2021 December 31, 2020
     (Unaudited)  
    ASSETS   
    Current assets   
    Cash and cash equivalents$68,812  $43,777 
    Grant receivable 109   109 
    Prepaid expenses and other current assets 1,651   543 
    Total current assets 70,572   44,429 
        
    Property and equipment, net 6   - 
    Deferred offering costs 2,352   - 
    Other assets 13   - 
    Total assets$72,943  $44,429 
        
    LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT   
    Current liabilities   
    Accounts payable$2,907  $531 
    Accrued expenses and other current liabilities 1,611   423 
    Preferred stock tranche rights liability -   5,033 
    Preferred stock warrant liability -   380 
    Total liabilities 4,518   6,367 
        
    Series A convertible preferred stock, $0.0001 par value; 711,203 shares authorized as of June 30, 2021 and December 31, 2020; 477,297 shares issued and outstanding as of June 30, 2021 and December 31, 2020; liquidation preference of $1,067 as of June 30, 2021 1,067   1,067 
    Series A-1 convertible preferred stock, $0.0001 par value; 11,898,177 shares authorized as of June 30, 2021 and December 31, 2020; 7,985,305 and 7,537,879 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively; liquidation preference of $18,097 as of June 30, 2021 22,963   16,333 
    Series B convertible preferred stock, $0.0001 par value; 29,457,450 shares authorized as of June 30, 2021 and December 31, 2020; 19,770,070 and 11,862,043 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively; liquidation preference of $75,116 as of June 30, 2021 150,474   39,253 
        
    Stockholders' deficit   
    Common stock, $0.0001 par value; 50,500,000 shares authorized as of June 30, 2021 and December 31, 2020, respectively; 556,570 and 419,124 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively -   - 
    Additional paid-in capital 9,241   8,374 
    Accumulated deficit (115,320)  (26,965)
    Total stockholders' deficit (106,079)  (18,591)
    Total liabilities, convertible preferred stock and stockholders' deficit$72,943  $44,429 
        



    Acumen Pharmaceuticals, Inc.
    Condensed Statements of Operations
    (in thousands, except share and per share data)
    (Unaudited)
            
     Three Months Ended June 30, Six Months Ended June 30,
      2021   2020   2021   2020 
    Grant and other revenue$-  $151  $-  $377 
            
    Operating expenses       
    Research and development 2,254   1,927   4,832   3,977 
    General and administrative 1,187   259   2,402   481 
    Total operating expenses 3,441   2,186   7,234   4,458 
    Loss from operations (3,441)  (2,035)  (7,234)  (4,081)
            
    Other income (expense)       
    Interest income 4   -   8   1 
    Change in fair value of preferred stock tranche rights liability and preferred stock warrant liability (57,940)  -   (81,157)  - 
    Other income 19   -   28   - 
    Total other income (expense) (57,917)  -   (81,121)  1 
    Net loss attributable to common stockholders$(61,358) $(2,035) $(88,355) $(4,080)
            
    Net loss per common share, basic and diluted$(141.93) $(4.86) $(207.52) $(9.73)
            
    Weighted-average shares outstanding, basic and diluted 432,325   419,124   425,761   419,124 
            



    Primary Logo

    View Full Article Hide Full Article
View All Acumen Pharmaceuticals Inc. News